+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07184619

Evaluating Evenamide 15 mg Twice Daily as Add-On Therapy in Adults with Treatment-Resistant Schizophrenia Compared to Placebo A 12-Week Randomized, Double-Blind Study

Led by Newron Pharmaceuticals SPA · Updated on 2026-09-10

400

Participants Needed

19

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of Evenamide, a glutamate release modulator, as an add-on treatment for adults with treatment-resistant schizophrenia TRS. The study aims to compare the effects of Evenamide 15 mg twice daily with a placebo, focusing on its efficacy, safety, and tolerability in patients who do not respond adequately to their current stable antipsychotic medications. This is a Phase III, randomized, double-blind, placebo-controlled trial involving approximately 400 participants. Participants will be randomly assigned to receive either Evenamide capsules 15 mg twice daily or matching placebo capsules twice daily, alongside their standard antipsychotic treatment, for a total of 12 weeks. The treatment period is designed to assess the added benefit of Evenamide compared to placebo when used as an add-on therapy. Both groups will follow the same dosing schedule, and neither participants nor researchers will know which treatment is being administered until the study is complete. Throughout the 12-week treatment, participants will undergo evaluations including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression scores, and assessments of personal and social performance and quality of life. Safety will be closely monitored by tracking adverse events during treatment and for 30 days after the treatment period ends. Participants adherence to prescribed antipsychotic treatment will be observed, and the total study duration includes the treatment phase plus a safety follow-up period.

CONDITIONS

Brief Title

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Research Team

N

Newron Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here